A Pilot Study To Evaluate The CreatiVasc Hemoaccess Valve System In Patients Requiring Arteriovenous Graft Placement
|ClinicalTrials.gov Identifier: NCT01644526|
Recruitment Status : Terminated (An enhanced device has been developed)
First Posted : July 19, 2012
Last Update Posted : February 2, 2018
|Condition or disease||Intervention/treatment|
|End Stage Renal Disease||Device: Hemoaccess Valve System|
The Hemoaccess Valve System (HVS) is a subcutaneous valve device that is implanted when a new AV graft is placed. A saline pump delivers fluid to the arterial balloon valve and closes that end of the graft off to blood flow. Using the dialysis blood lines, saline flushes residual blood from the graft back into the body. Then the venous balloon valve closes and heparinized saline resides in the graft between dialysis sessions.
When the patient returns for dialysis, the dialysis technician deflates the valves and allows blood to flow to the graft for dialysis. (The saline inside the graft simply enters the blood stream.)
By only having saline inside the AV graft between dialysis sessions, there is no post-dialysis bleeding where the dialysis needles were cannulated, and because blood flow is restored to its normal course in the vein and artery, the traditional turbulent blood flow through the graft is eliminated, reducing the traditional complications caused when arterial blood is diverted through the graft then into the vein.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Device Feasibility|
|Official Title:||A Pilot Study To Evaluate The CreatiVasc Hemoaccess Valve System In Patients Requiring Arteriovenous Graft Placement|
|Actual Study Start Date :||January 2016|
|Primary Completion Date :||June 30, 2017|
|Study Completion Date :||July 31, 2017|
Experimental: Hemoaccess Valve System
Valve system for use with AV graft
Device: Hemoaccess Valve System
Device that allows blood to selectively flow into an arteriovenous graft to provide vascular access for dialysis then turn off the flow of blood to the graft in between dialysis sessions.
- Unassisted patency rate [ Time Frame: 12 months ]Determine if the ability to limit blood flow to an AV graft only when it is needed for dialysis will increase unassisted patency rate of the test arm by a minimum of 50%. The New England Journal of Medicine study, "Effect of Dipyridamole plus Aspirin on Hemodialysis Graft Patency" (NEJM 360;21, 5/21/09) indicated a 1 year unassisted patency rate of 23% (77% required intervention). Our objective is to determine if the intervention rate can be reduced to 38-39% during the study, a 50% reduction in the expected intervention rate.
- Eliminate Post-Dialysis Needle Site Bleeding [ Time Frame: 12 months ]
Outcome measure: Reduce post-dialysis needle site bleeding by 95%.
Currently most dialysis patients experience mild to severe post-dialysis bleeding when the large (15 gauge) dialysis needles are removed from their AV graft. The HVS device shuts off blood flow to the graft after dialysis therefore no post-dialysis bleeding should be experienced.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01644526
|United States, South Carolina|
|Greenville, South Carolina, United States, 29615|
|Study Director:||Robert Scribner||CEO|